What the Vet Never Sees: the Case for Pet Health Monitoring Devices in Canine Epilepsy

Your customer's dog recently had a seizure. She found what happened the moment she came back from work, seeing the wet patch on the rug, a disoriented and exhausted dog, and a timestamp she could only estimate.

She went back to the vet, reported what she knew, which was, almost nothing, and the vet examined the dog. Everything looked normal, the vet adjusted the medication, and sent the woman and her dog back home.

The problem here is that nobody knew what happened to the dog. It is not a failure of the vet care. It is a structural problem at the center of canine epilepsy. But it is also something that a pet health monitoring device for epilepsy can help with.

Why Epilepsy is Difficult to Monitor in Dogs

Chronic conditions often leave evidence behind that vets can look at. That includes blood panels, imaging, weight trends, or coat condition. Epilepsy, however, leaves no trace.

The data from the Merck Veterinary Manual shows that canine epilepsy affects between 0.5% and 0.82% of dogs in nonreferral practice, rising to between 1% and 2.6% in referral hospital populations. In some breeds, those numbers are much higher.

What makes the condition difficult is not diagnosis. It is what happens between appointments.

A 2022 paper published in Frontiers in Veterinary Science on managing dog and owner health in canine epilepsy noted that veterinarians will typically only examine dogs during the interictal period - the clinically normal window between seizures - and that not witnessing the seizure event directly can limit a vet's understanding of how the condition is actually progressing. The seizure diary, which is the standard monitoring tool, depends entirely on an owner being present when a seizure occurs, recognizing it correctly, and recording it accurately. None of those conditions are reliably met.

Drug resistance compounds the problem further. A review published in PMC, examining the prospects of non-EEG seizure detection in dogs, put the drug-resistant rate at approximately 25% to 30% of dogs with idiopathic epilepsy. A 2022 study on phenobarbital-resistant cases in Frontiers in Veterinary Science noted treatment success rates - defined as extending the inter-seizure interval threefold - of roughly 14% with add-on pregabalin and 8% with levetiracetam dose increases. The efficacy ceiling on first-line treatments is not much higher: a quality-of-life study published in the same journal reported phenobarbital efficacy at 70% to 80%, bromide at 60%, and imepitoin at 50%.

What this means in practice is that a meaningful share of dogs on anti-seizure medication are still seizing, their owners are still struggling to accurately count how often, and vets are calibrating treatment on information that is structurally incomplete.

What Do Owners Miss?

A seizure is not only a convulsive event. It produces measurable cardiac and autonomic changes before, during, and after the ictal phase, and most of those changes are invisible without continuous monitoring.

Research on cardiac autonomic nervous system disturbances in dogs with idiopathic epilepsy, published in ScienceDirect, showed that dogs in the interictal period exhibit subclinical changes in cardiac conduction, including increased P-wave duration and QTc interval. These are not changes that an owner watching a dog eat breakfast would notice.

During a seizure, the autonomic picture is more pronounced. A review of non-EEG seizure detection methods in dogs, published in PMC, described ictal tachycardia as the most consistently recorded cardiovascular change, driven by sympathetic activation, catecholamine release, and increased neuronal firing. Heart rate variability, rather than heart rate alone, is considered the more sensitive measure because it captures the autonomic shift more completely than a simple rate reading.

The post-ictal period carries its own clinical weight. A 2025 study published in PMC and based on questionnaire data from owners of 87 dogs with idiopathic epilepsy found post-ictal signs in 91% of dogs with generalized seizures. The median duration was 30 minutes, but the range ran from 5 minutes to 4,320 minutes - more than 72 hours. The most common signs were disorientation and clumsiness. The study also found that post-ictal signs had a greater impact on quality of life than ictal signs themselves.

For an owner sending a dog to her seizure diary: she is missing the 30-minute recovery, the HRV disturbance that preceded it, and any seizures that happened while she was not in the room.

What Continuous Monitoring Changes

The reason a pet health monitoring device for epilepsy is a different category of product from an activity tracker is this: epilepsy management requires physiological data, not behavioral data.

An accelerometer can detect the violent movement of a generalized tonic-clonic seizure under the right conditions. A 2025 study published in Frontiers in Veterinary Science by Hirashima and colleagues evaluated an app-based seizure detection system in a clinical setting and reported a sensitivity of 74.3% - detecting 25 out of 34 generalized tonic-clonic seizures. That study noted three false positives in one dog. The system is not yet commercially available.

The more clinically meaningful opportunity is not seizure detection in isolation. It is continuous baseline monitoring that allows a vet to see what is happening between seizures: resting heart rate trends, HRV patterns, respiratory rate, and sleep quality. That data is what a seizure diary does not capture. It is also what makes a follow-up appointment useful. A vet reviewing three weeks of continuous physiological data from a dog on phenobarbital is calibrating differently than a vet reviewing an owner's written log.

The PHH-23 From PuresPet

For pet brands evaluating hardware for the epilepsy monitoring use case, the PHH-23 is a sourcing option built around a BCG sensor architecture rather than accelerometer-only design.

Ballistocardiography measures the micro-mechanical forces the body generates with each heartbeat, capturing heart rate, respiratory rate, and heart rate variability without requiring skin contact, electrodes, or fur shaving. The PHH-23 monitors all three metrics continuously on a 24/7 basis. It also produces a BCG curve and generates HRV reports, sleep analysis, and health summaries, with abnormal readings flagged for review through a companion app compatible with both Android and iOS.

The GPS layer adds 4G Cat.1 cellular connectivity with positioning through GPS, BDS, AGPS, LBS, and Wi-Fi triangulation to a stated accuracy of three to five meters. The app includes electronic geofencing with escape alerts, real-time location, and historical trajectory playback.

Specifications for brands evaluating sourcing: the device weighs 55 grams, measures 125 x 34 x 14mm, and runs on a 750mAh lithium battery providing three days of working time. It is IP6 rated for water resistance and carries CE and FCC certification. Minimum order quantity is 100 units per color per size. Production lead time is 20 to 25 days. OEM and ODM services are available, with logo customization by laser or screen print and custom packaging.

The design distinction that matters for the epilepsy use case: the PHH-23 was built around BCG monitoring first. Most combined devices in this category work the other way - GPS-first, with health data as a secondary feature. The sensor architecture reflects which job the device was designed to do. A BCG device produces the kind of data that a vet reviewing interictal cardiac function actually needs. An accelerometer-based device produces step counts and motion alerts.

More information on the PHH-23 is available at purespet.com.

Frequently Asked Questions

Can a wearable device detect seizures in dogs?

Wearable devices can detect generalized tonic-clonic seizures because these seizures produce strong enough movement that accelerometers can catch. But these devices can also track heart rate, HRV, and respiratory rate between seizures.

What is the monitoring gap in canine epilepsy?

The monitoring gap refers to the period between veterinary appointments during which an owner is the only source of information about seizure activity. Vets examine dogs in the clinically normal interictal period and rarely witness a seizure directly. Standard seizure diaries depend on owner presence and accurate recall, both of which are inconsistent. Continuous wearable monitoring addresses the problem by capturing physiological data around the clock, providing vets with objective information for treatment decisions.

Why is epilepsy so hard to treat in dogs?

The two main challenges are unpredictability and drug resistance. Seizures do not announce themselves, which makes it difficult to gather consistent data on frequency and severity. Drug resistance affects approximately 25% to 30% of dogs with idiopathic epilepsy according to multiple published reviews, and even first-line medications have efficacy ceilings: phenobarbital works in roughly 70% to 80% of cases, bromide in around 60%, and imepitoin in approximately 50%. Treatment adjustments are made on the basis of owner-reported data, which is often incomplete. Better monitoring data - particularly continuous physiological monitoring - gives vets more to work with.

What does HRV tell you about a dog with epilepsy?

Heart rate variability reflects the balance between the sympathetic and parasympathetic branches of the autonomic nervous system. In dogs with idiopathic epilepsy, research published in ScienceDirect found measurable HRV and cardiac conduction changes even in the interictal period - the clinically normal window between seizures. During and after seizures, HRV shifts are more pronounced. A review published in PMC identified HRV as the preferred metric for non-EEG seizure monitoring because it captures the autonomic response more completely than heart rate alone. Tracking HRV continuously between seizures can surface changes that would otherwise go unnoticed until the next vet visit.

What should pet brands know about the epilepsy monitoring market?

Dog owners managing epilepsy are among the most engaged pet health consumers. They research medication, track symptoms, and make purchasing decisions based on functional specificity - not general wellness claims. A device that monitors heart rate, HRV, and respiratory rate continuously is a materially different product for this customer than one that counts steps. The commercial opportunity lies in positioning wearable devices accurately: as tools that close the monitoring gap between vet appointments, not as seizure alarms.

What this means for your product line

The dog owner managing epilepsy is not a casual wellness buyer. She has read the medication insert. She has a seizure diary she knows is incomplete. She has sat on a vet appointment explaining something she did not see and gone home with a medication adjustment she cannot quite evaluate.

That owner is not buying a health monitoring device because it sounds like a good idea. She is buying because she has experienced the cost of not having data. That is a customer who will leave a review, recommend the product to the next owner in her breed group, and contact support when she has a question about what the HRV report means.

Brands that understand what this customer is actually trying to solve - close the gap, give the vet something real to work with, sleep through the night knowing the app will alert them - are the ones positioned to earn that customer. Brands that market a step counter with a health label are not.

The device infrastructure to serve this customer exists. The question is whether your product line reflects what she actually needs.